Biogen is placing a $1.15 billion bet on Chris Viehbacher’s diversification vision. The upfront payment has secured Biogen a deal to buy Human Immunology Biosciences (HI-Bio), a biotech that is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications.
Viehbacher identified Biogen’s focus on neuroscience as a problem after he took over as CEO of the Big Biotech. For a company of its size, Biogen was too narrowly focused, Viehbacher reckoned, and that was particularly troublesome because its pipeline skewed toward high-risk neuroscience programs. The CEO responded to the perceived problem by outlining plans to expand in other areas, notably immunology.
That plan took off Wednesday, when Biogen disclosed a deal to buy HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments. The deal will give Biogen control of the anti-CD38 antibodyfelzartamab.
“We believe this late-stage asset, which has demonstrated impact on key biomarkers and clinical endpoints in three renal diseases with serious unmet needs, is a strategic addition to the Biogen portfolio as we continue to augment our pipeline and build on our expertise in immunology,” Priya Singhal, M.D., head of development at Biogen, said in a statement.
The biotech plans to run phase 3 trials in AMR, PMN and IgAN. The breadth of the program, coupled to the potential to target other immune-mediated diseases such as lupus, gives Biogen an opportunity to significantly expand its presence in immunology through a single pipeline-in-a-product, provided the molecule succeeds in the clinic.
MorphoSys took HI-Bio equity as part of the deal, ending last year with a 12% stake in the firm. Novartis, which struck a deal to buy MorphoSys, could be the beneficiary of the sale of the stake.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.